CYC 140, from Cyclacel Pharmaceuticals, inhibits Plk1 with an IC50 of 3 nM in vitro, and has demonstrated antitumor activity in human tumor xenografts at non-toxic doses [71]. Here, PLK1 is linked to neoplasm.